BioCentury | Aug 11, 2008
Emerging Company Profile

CoLucid: Safety in the CNS

...of two NCEs from the stigmine platform. The stigmine platform was acquired in 2005 from Sention Inc....
BioCentury | May 23, 2005
Company News

Cubist management update

...Infectious Hired: David Mantus as VP of regulatory affairs, formerly VP of regulatory affairs at Sention Inc. WIR...
BioCentury | May 2, 2005
Finance

MPM's portfolio

...and wts 4/30/03 $46.0 Nick Simon Rinat Neurology U.S. Series B 8/19/03 $40.0 Dennis Henner Sention...
BioCentury | Jan 24, 2005
Company News

Sention, Merck deal

...MRK granted Sention exclusive rights to a family of preclinical mGluR5 receptor antagonists for Down Syndrome...
...compounds for Huntington's disease. Sention is developing candidates for cognitive impairment and other CNS disorders. Sention Inc....
BioCentury | Jan 19, 2005
Company News

Sention, Merck neurology deal

...MRK granted Sention (Providence, R.I.) exclusive rights to a family of preclinical mGluR5 receptor antagonists for...
...retardation. The neurology company also received an option to license the compounds for Huntington's disease. Sention...
BioCentury | Jun 7, 2004
Strategy

Venture portfolio balancing

...Pharmaceuticals Inc. (South San Francisco, Calif.), formulation play TransForm Pharmaceuticals Inc. (Lexington, Mass.), memory company Sention Inc....
BioCentury | Mar 25, 2002
Finance

Neuro money

...Partners; Arch Venture Partners; Montreux Equity Partners; CalPERS; TIAA; Duke University; University of North Carolina Sention...
BioCentury | Feb 19, 2002
Company News

Sention board of directors update

Sention Inc., Providence, R.I. Business: Neurological Appointed: Nicholas Galakatos, general partner at MPM Capital L.P. WIR Staff Neurology...
BioCentury | Feb 12, 2002
Financial News

Sention raises $13 million

...Sention raised $13 million in a private financing through MPM Capital and Burrill & Co. Sention...
Items per page:
1 - 9 of 9
BioCentury | Aug 11, 2008
Emerging Company Profile

CoLucid: Safety in the CNS

...of two NCEs from the stigmine platform. The stigmine platform was acquired in 2005 from Sention Inc....
BioCentury | May 23, 2005
Company News

Cubist management update

...Infectious Hired: David Mantus as VP of regulatory affairs, formerly VP of regulatory affairs at Sention Inc. WIR...
BioCentury | May 2, 2005
Finance

MPM's portfolio

...and wts 4/30/03 $46.0 Nick Simon Rinat Neurology U.S. Series B 8/19/03 $40.0 Dennis Henner Sention...
BioCentury | Jan 24, 2005
Company News

Sention, Merck deal

...MRK granted Sention exclusive rights to a family of preclinical mGluR5 receptor antagonists for Down Syndrome...
...compounds for Huntington's disease. Sention is developing candidates for cognitive impairment and other CNS disorders. Sention Inc....
BioCentury | Jan 19, 2005
Company News

Sention, Merck neurology deal

...MRK granted Sention (Providence, R.I.) exclusive rights to a family of preclinical mGluR5 receptor antagonists for...
...retardation. The neurology company also received an option to license the compounds for Huntington's disease. Sention...
BioCentury | Jun 7, 2004
Strategy

Venture portfolio balancing

...Pharmaceuticals Inc. (South San Francisco, Calif.), formulation play TransForm Pharmaceuticals Inc. (Lexington, Mass.), memory company Sention Inc....
BioCentury | Mar 25, 2002
Finance

Neuro money

...Partners; Arch Venture Partners; Montreux Equity Partners; CalPERS; TIAA; Duke University; University of North Carolina Sention...
BioCentury | Feb 19, 2002
Company News

Sention board of directors update

Sention Inc., Providence, R.I. Business: Neurological Appointed: Nicholas Galakatos, general partner at MPM Capital L.P. WIR Staff Neurology...
BioCentury | Feb 12, 2002
Financial News

Sention raises $13 million

...Sention raised $13 million in a private financing through MPM Capital and Burrill & Co. Sention...
Items per page:
1 - 9 of 9